Focal Segmental Glomerulosclerosis | Treatment Algorithms: Claims Data Analysis | US | 2025
Focal segmental glomerulosclerosis (FSGS) is a kidney disease in which scarring occurs to the glomeruli. Although no drug therapies are approved for FSGS, physicians often prescribe RAAS inhibitors off-label to reduce proteinuria, and diuretics are commonly used to treat symptoms. Corticosteroid and immunosuppressive therapies are also considered for FSGS associated with clinical features of the nephrotic syndrome. However, owing to FSGS’s various etiologies and differences in presentation, management of the disease must be individualized. This report examines how key current therapies are being used to treat newly diagnosed and recently treated FSGS patients.
Questions answered
- What patient shares do key therapies garner by line of therapy in newly diagnosed FSGS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed FSGS patients?
- How are corticosteroids integrated into the treatment algorithm, and what is their source of business?
- What percentage of FSGS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of FSGS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States.
Key drugs: Alkylating agents, corticosteroids, diuretics, RAAS inhibitors.
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
